Session » (2141–2176) RA – Treatments Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2167

24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)

9:00AM-11:00AM: Abstract Number: 2142

Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors

9:00AM-11:00AM: Abstract Number: 2146

After JAK Inhibitor Failure, “Switching” or “Cycling”?

9:00AM-11:00AM: Abstract Number: 2149

Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors

9:00AM-11:00AM: Abstract Number: 2176

Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2171

Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?

9:00AM-11:00AM: Abstract Number: 2158

Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON

9:00AM-11:00AM: Abstract Number: 2169

Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial

9:00AM-11:00AM: Abstract Number: 2148

Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial

9:00AM-11:00AM: Abstract Number: 2151

Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2153

Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2165

Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up

9:00AM-11:00AM: Abstract Number: 2143

Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study

9:00AM-11:00AM: Abstract Number: 2156

Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study

9:00AM-11:00AM: Abstract Number: 2157

Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis

9:00AM-11:00AM: Abstract Number: 2141

Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)

9:00AM-11:00AM: Abstract Number: 2174

JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib

9:00AM-11:00AM: Abstract Number: 2166

Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study

9:00AM-11:00AM: Abstract Number: 2150

Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients

9:00AM-11:00AM: Abstract Number: 2163

Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?

9:00AM-11:00AM: Abstract Number: 2145

Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study

9:00AM-11:00AM: Abstract Number: 2144

Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study

9:00AM-11:00AM: Abstract Number: 2161

Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501

9:00AM-11:00AM: Abstract Number: 2160

Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes

9:00AM-11:00AM: Abstract Number: 2175

Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study

9:00AM-11:00AM: Abstract Number: 2164

Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2159

Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic

9:00AM-11:00AM: Abstract Number: 2147

Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East

9:00AM-11:00AM: Abstract Number: 2162

Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure

9:00AM-11:00AM: Abstract Number: 2172

Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients

9:00AM-11:00AM: Abstract Number: 2152

Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 2170

Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study

9:00AM-11:00AM: Abstract Number: 2155

The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies

9:00AM-11:00AM: Abstract Number: 2168

The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2154

Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs

9:00AM-11:00AM: Abstract Number: 2173

Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients

« View all sessions from this meeting